Product Description
Phenindione is a beta-diketone and an aromatic ketone. It has a role as an anticoagulant. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Phenindione)
Mechanisms of Action: Vitamin K Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Malta | Russia | Taiwan | Ukraine | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Pregnancy Outcomes|Stroke|Atrial Fibrillation|Atrial Flutter|Subarachnoid Hemorrhage|Cerebral Hemorrhage|Ventricular Fibrillation|Ventricular Flutter|Intracranial Hemorrhage, Hypertensive|Cerebrovascular Disorders|Cerebral Small Vessel Diseases|Intracranial Hemorrhages|Hematoma, Subdural, Intracranial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Start or STop Anticoagulants Randomised Trial (SoSTART) | P3 |
Unknown status |
Atrial Fibrillation|Stroke |
2022-09-11 |
|
| SoSTART | P3 |
Completed |
Hematoma, Subdural, Intracranial|Intracranial Hemorrhage, Hypertensive|Cerebral Small Vessel Diseases|Cerebrovascular Disorders|Atrial Fibrillation|Ventricular Flutter|Intracranial Hemorrhages|Ventricular Fibrillation|Cerebral Hemorrhage|Subarachnoid Hemorrhage|Atrial Flutter |
2021-03-26 |
|
| BEST-AF | N/A |
Completed |
Atrial Fibrillation |
2020-07-16 |
|
| AINSHAMS2012 | P3 |
Completed |
Pregnancy Outcomes |
2012-06-01 |